CorEvitas Registry study of Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted in modest, nonsignificant improvement axial outcomes,(irrespective HLA-B27 status), including ASDAS40, BASDAI50, & spinal pain. 31% of pts were B27+ https://t.co/9m9H7PwIIF #PsAlways https://t.co/dYk5GfIdez